Copyright
©The Author(s) 2015.
World J Hepatol. Sep 18, 2015; 7(20): 2245-2263
Published online Sep 18, 2015. doi: 10.4254/wjh.v7.i20.2245
Published online Sep 18, 2015. doi: 10.4254/wjh.v7.i20.2245
Figure 1 An illustrative case showing discrepancies between subsequent criteria used to assess tumor response in a patient treated with sorafenib for hepatocellular carcinoma.
HCC: Hepatocellular carcinoma; CT: Computed tomography; RECIST: Response evaluation criteria in solid tumors; mRECIST: Modified RECIST.
- Citation: Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20): 2245-2263
- URL: https://www.wjgnet.com/1948-5182/full/v7/i20/2245.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i20.2245